Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Ludwig Edward J.Director | Boston ScientificBSX | Open-market buy | 05/20 | 05/21 | 3,580 sh | $56.68 | $202,914.4 | +16.4% |
Boston ScientificBSX | Open-market buy | 05/19–05/20 | 05/21 | 4,450 sh2 trades | $56.43avg. | $251,110 | +47.2% | |
Cheryl PegusDirector | Boston ScientificBSX | Open-market buy | 05/20 | 05/21 | 1,770 sh | $56.49 | $99,987.3 | No record |
Boston ScientificBSX | Open-market sale10b5-1 plan | 02/02 | 02/03 | 160,901 sh2 trades | $93.49avg. | $15,043,318.49 | −10.2% | |
Arthur C. ButcherEVP& Grp Pres, MedSurg & APAC | Boston ScientificBSX | Open-market sale10b5-1 plan | 25/12/01 | 25/12/02 | 17,313 sh | $101.55 | $1,758,135.15 | −42.3% |
Zane Ellen M.Director | Boston ScientificBSX | Open-market sale10b5-1 plan | 25/11/06 | 25/11/06 | 12,891 sh | $98.28 | $1,266,927.48 | −34.8% |
Boston ScientificBSX | Open-market sale10b5-1 plan | 25/11/03 | 25/11/04 | 50,000 sh3 trades | $99.47avg. | $4,973,291.36 | −21.9% | |
Boston ScientificBSX | Open-market sale10b5-1 plan | 25/10/27–25/10/28 | 25/10/28 | 12,891 sh2 trades | $101.38avg. | $1,306,886.94 | −34.8% | |
Boston ScientificBSX | Open-market sale10b5-1 plan | 25/10/01 | 25/10/01 | 50,000 sh2 trades | $98.47avg. | $4,923,369.85 | −21.9% | |
Boston ScientificBSX | Open-market sale10b5-1 plan | 25/09/02 | 25/09/03 | 50,000 sh2 trades | $105.43avg. | $5,271,543.2 | −21.9% | |
Joseph Michael FitzgeraldEVP & Group Pres, Cardiology | Boston ScientificBSX | Open-market sale10b5-1 plan | 25/08/01 | 25/08/04 | 50,000 sh | $104.63 | $5,231,500 | −21.9% |
Arthur C. ButcherEVP& Grp Pres, MedSurg & APAC | Boston ScientificBSX | Open-market sale10b5-1 plan | 25/08/01 | 25/08/04 | 17,313 sh | $104.63 | $1,811,459.19 | −42.3% |
Yoshiaki FujimoriDirector | Boston ScientificBSX | Open-market sale | 25/07/29 | 25/07/30 | 2,901 sh | $106.99 | $310,377.99 | −58.2% |
Ludwig Edward J.Director | Boston ScientificBSX | Open-market sale | 25/07/25 | 25/07/28 | 4,000 sh | $106.03 | $424,120 | −17.8% |
Joseph Michael FitzgeraldEVP & Group Pres, Cardiology | Boston ScientificBSX | Open-market sale10b5-1 plan | 25/07/01 | 25/07/02 | 50,000 sh | $106.97 | $5,348,500 | −21.9% |
Joseph Michael FitzgeraldEVP & Group Pres, Cardiology | Boston ScientificBSX | Open-market sale10b5-1 plan | 25/06/04 | 25/06/04 | 56,372 sh | $102.88 | $5,799,551.36 | −24.0% |
Boston ScientificBSX | Open-market sale10b5-1 plan | 25/06/02 | 25/06/03 | 164,443 sh2 trades | $103.69avg. | $17,050,946.29 | −10.0% | |
Ludwig Edward J.Director | Boston ScientificBSX | Open-market sale | 25/05/29 | 25/05/30 | 4,000 sh | $104.59 | $418,360 | −15.1% |
Vance R. BrownSVP, GC and Corp. Secretary | Boston ScientificBSX | Open-market sale10b5-1 plan | 25/05/21 | 25/05/22 | 4,826 sh | $106.42 | $513,582.92 | −13.3% |
John Bradley SorensonEVP, Global Operations | Boston ScientificBSX | Open-market sale10b5-1 plan | 25/05/05 | 25/05/06 | 4,572 sh | $104.54 | $477,956.88 | −19.6% |